Cargando…

SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation

While the respiratory tract is the primary route of entry for SARS-CoV-2, evidence shows that the virus also impacts the central nervous system. Intriguingly, case reports have documented SARS-CoV-2 patients presenting with demyelinating lesions in the brain, spinal cord, and optic nerve, suggesting...

Descripción completa

Detalles Bibliográficos
Autores principales:	MacDougall, Madison, El-Hajj Sleiman, Jad, Beauchemin, Philippe, Rangachari, Manu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102605/ https://www.ncbi.nlm.nih.gov/pubmed/35572514 http://dx.doi.org/10.3389/fimmu.2022.871276

Ejemplares similares

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
por: Bellucci, Gianmarco, et al.
Publicado: (2021)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

The Non-Obese Diabetic Mouse Strain as a Model to Study CD8(+) T Cell Function in Relapsing and Progressive Multiple Sclerosis
por: Ignatius Arokia Doss, Prenitha Mercy, et al.
Publicado: (2015)

Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation
por: Steelman, Andrew J.
Publicado: (2015)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
por: Pugliatti, Maura, et al.
Publicado: (2022)

SARS-CoV-2 Exacerbates COVID-19 Pathology Through Activation of the Complement and Kinin Systems
por: Savitt, Anne G., et al.
Publicado: (2021)

Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
por: Severa, Martina, et al.
Publicado: (2020)

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
por: Groß-Albenhausen, Elina, et al.
Publicado: (2023)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
por: Gröning, Remigius, et al.
Publicado: (2023)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
por: Mueller-Enz, Magdalena, et al.
Publicado: (2023)

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
por: Woopen, Christina, et al.
Publicado: (2022)

Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study
por: Idda, Maria Laura, et al.
Publicado: (2022)

Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis
por: Maglione, Alessandro, et al.
Publicado: (2023)

Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
por: Sallenave, Jean-Michel, et al.
Publicado: (2020)

Biological Sex As a Critical Variable in CD4(+) Effector T Cell Function in Preclinical Models of Multiple Sclerosis
por: Umair, Muhammad, et al.
Publicado: (2022)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
por: Iannetta, Marco, et al.
Publicado: (2022)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2
por: Sarker, Hassan, et al.
Publicado: (2022)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Editorial: Lymphocytes in MS and EAE: More Than Just a CD4(+) World
por: Rangachari, Manu, et al.
Publicado: (2017)

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273
por: Verstegen, Niels JM, et al.
Publicado: (2022)

Systematic review of prediction models in relapsing remitting multiple sclerosis
por: Brown, Fraser S., et al.
Publicado: (2020)

Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses
por: Milo, Ron, et al.
Publicado: (2022)

A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains
por: Nakandakari-Higa, Sandra, et al.
Publicado: (2022)

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
por: Liang, Yanwen, et al.
Publicado: (2020)

SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
por: Schmidt, Katja G., et al.
Publicado: (2021)

Multiple sclerosis following SARS-CoV-2 infection
por: Palao, M., et al.
Publicado: (2020)

SARS-CoV-2 triggered relapse of multiple sclerosis
por: Finsterer, Josef
Publicado: (2022)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Cannabidiol and SARS-CoV-2 Infection
por: Vallée, Alexandre
Publicado: (2022)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses
por: Cao, Yingying, et al.
Publicado: (2021)

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
por: Diaz de la Fe, Amado, et al.
Publicado: (2021)

SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis()
por: Piñar Morales, R., et al.
Publicado: (2021)

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization
por: Tang, Haijun, et al.
Publicado: (2022)

Immunomodulatory Drugs in the Management of SARS-CoV-2
por: Burrage, Daniel R., et al.
Publicado: (2020)

Immunity to SARS-CoV-2: Lessons Learned
por: Fergie, Jaime, et al.
Publicado: (2021)

CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ilj9ig34cc237247kvh4psmib8